In December 2019, numerous coronavirus disease 2019 (COVID-19) cases were reported in Wuhan, China, which has since spread throughout the world. However, its impact on rheumatoid arthritis (RA) patients is unknown. Herein, we report a case of COVID-19 pneumonia in a 61-year-old female RA patient who was receiving conventional disease-modifying antirheumatic drugs (cDMARDs). The patient presented with a 4-day history of myalgia and febrile sensation. COVID-19 was confirmed by real-time polymerase chain reaction (PCR). Chest X-ray showed increased opacity on the right lower lung area, and C-reactive protein level was slightly elevated. The patient was treated with antiviral agents (lopinavir/ritonavir), and treatment with cDMARDs was discontinued except hydroxychloroquine. Her symptoms and laboratory results gradually improved. Three weeks later, real-time PCR for COVID-19 showed negative conversion, and the patient was discharged without any complications.
4 November 2025 in Scandinavian Journal of Rheumatology
Systemic lupus erythematosus (SLE) is associated with increased cancer risk. However, the patterns of cancer incidence remain unclear. This study aimed to evaluate the cancer risk in patients with SLE. This population-based cohort study identified 24 241 patients with newly diagnosed SLE between 2004 and 2020 using Korean National Health Insurance Service data. Patients were followed up until cancer diagnosis, death, or December 2021. Standardized incidence ratios (SIRs) were calculated to compare cancer risk between patients with SLE and the general population. Subgroup analyses were performed based on the age at diagnosis, follow-up duration, and use of immunosuppressive agents. Patients with SLE had higher risks of overall [SIR 3.3, 95% confidence interval (CI) 3.2-3.4], solid (SIR 3.1, 95% CI 3.0-3.2), and haematological (SIR 9.8, 95% CI 8.9-10.9) cancers compared with the general population. Among solid cancers, liver cancer had the highest risk, followed by ovarian cancer. The relative cancer risk peaked among patients aged 20-39 years (SIR 4.9, 95% CI 4.6-5.2) and during the first year after diagnosis (SIR 4.7, 95% CI 4.3-5.1). The SIRs for haematological, cervical, and lung cancers in cyclophosphamide-treated patients were higher than those for the corresponding cancers in the overall SLE population. Patients with SLE have increased cancer risk compared with the general population. Increased relative cancer risk is associated with younger age, first year post-diagnosis, and cyclophosphamide treatment.
Background/Aims: Serum uric acid (SUA) is a potential risk factor for renal involvement in systemic lupus erythematosus (SLE). However, the impact of cumulative SUA levels on subsequent renal involvement in premenopausal women remains unclear. The association between cumulative SUA levels and the development of subsequent renal involvement in premenopausal patients with SLE was evaluated. Materials and Methods: A retrospective review of 112 premenopausal women with newly diagnosed SLE, and no renal involvement at diagnosis was conducted in a tertiary medical center. Clinical characteristics at diagnosis and during follow-up were compared between patients who developed subsequent renal involvement and those who did not. Timeaveraged SUA (TA-SUA) was calculated from the area under the curve during follow-up. Cox proportional hazards analysis was performed to evaluate the factors associated with subsequent renal involvement. Results: The median TA-SUA level among 112 patients was 4.2 mg/dL (IQR, 3.8-4.8). During a median follow-up of 4.4 years, 25 patients developed subsequent renal involvement. The proportion of patients with TA-SUA level ≥4.2 mg/dL was higher in patients with subsequent renal involvement than in those without (84.0% vs. 46.0%, P = .001). In multivariate Cox analysis, TA-SUA level ≥4.2 mg/dL was associated with a higher risk of subsequent renal involvement (hazard ratio 6.389, P = .014). Systemic lupus erythematosus disease activity index score and the presence of anti-Smith antibodies at diagnosis were also associated with subsequent renal involvement. Conclusion: High TA-SUA levels are independently associated with an increased risk of subsequent renal involvement in premenopausal patients with SLE, underscoring the importance of cumulative SUA levels.Cite this article as: Choi SJ, So MW, Yoo KD, Lee SG, Choi SW, Lim DH. Association between time-averaged serum uric acid level and subsequent renal involvement in premenopausal patients with systemic lupus erythematosus. Arch Rheumatol. 2025;40(4):427-434.